Severe immune-related hepatitis induced by immune checkpoint inhibitors: Clinical features and management proposal-Reference-Cited by-同舟云学术

Severe immune-related hepatitis induced by immune checkpoint inhibitors: Clinical features and management proposal

Published:2021-03 Issue:2 Volume:45 Page:101491
ISSN:2210-7401
Container-title:Clinics and Research in Hepatology and Gastroenterology
language:en
Short-container-title:Clinics and Research in Hepatology and Gastroenterology

Author:

Gauci Marie-Léa,Baroudjian Barouyr,Bédérède Ulysse,Zeboulon Charlotte,Delyon Julie,Allayous Clara,Madelaine Isabelle,Eftekhari Pirayeh,Resche-Rigon Matthieu,Poté Nicolas,Paradis Valerie,Durand François,Lebbé Céleste,Roux Olivier,Bouattour Mohamed

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference28 articles.

1. Improved survival with ipilimumab in patients with metastatic melanoma;Hodi;N Engl J Med,2010

2. Nivolumab in previously untreated melanoma without BRAF mutation;Robert;N Engl J Med,2015

3. Pembrolizumab versus Ipilimumab in Advanced Melanoma;Robert;N Engl J Med,2015

4. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma;Motzer;N Engl J Med,2015

5. The role of anti-PD-1 and anti-PD-L1 agents in the treatment of diffuse large B-cell lymphoma: The future is now;Juárez-Salcedo;Crit Rev Oncol Hematol,2017

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Glucocorticoid efficacy and treatment strategies for drug-induced liver injury: a literature review;Molecular Biology Reports;2024-07-31

2. Infliximab in steroid-refractory immune-related hepatitis does not demonstrate hepatotoxicity and may shorten time on steroids;Journal for ImmunoTherapy of Cancer;2024-07

3. The Epidemiology of Newly Recognized Causes of Drug-Induced Liver Injury: An Update;Pharmaceuticals;2024-04-18

4. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU;Gastroenterología y Hepatología;2024-04

5. New advances in the study of PD-1/PD-L1 inhibitors-induced liver injury;International Immunopharmacology;2024-04